Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14969MR)

This product GTTS-WQ14969MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14969MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ722MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ11837MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ7242MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ6602MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6864MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ169MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ12784MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ14460MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW